Revolution Medicines (RVMD) Receives a Buy from Piper Sandler

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Revolution Medicines (RVMD – Research Report), with a price target of $43.00. The company’s shares closed yesterday at $38.31.

According to TipRanks, Catanzaro is a 4-star analyst with an average return of 8.4% and a 40.00% success rate. Catanzaro covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Iovance Biotherapeutics, and ImmunityBio.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Revolution Medicines with a $42.44 average price target, implying a 10.78% upside from current levels. In a report released today, Needham also reiterated a Buy rating on the stock with a $46.00 price target.

The company has a one-year high of $40.21 and a one-year low of $15.44. Currently, Revolution Medicines has an average volume of 1.49M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Revolution Medicines (RVMD) Company Description:

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.